News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MabCure, Inc. Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents


3/19/2012 8:10:17 AM

NEW YORK--(BUSINESS WIRE)--MabCure Inc., (OTCBB:MBCI) a leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES